Cargando…
Review of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease
Deutetrabenazine was recently approved for the treatment of chorea in Huntington’s disease (HD) and is the first deuterated medication that has been US Food and Drug Administration (FDA)-approved for therapeutic use. In this article, we review deutetrabenazine’s drug design, pharmacokinetics, drug i...
Autores principales: | Dean, Marissa, Sung, Victor W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818866/ https://www.ncbi.nlm.nih.gov/pubmed/29497277 http://dx.doi.org/10.2147/DDDT.S138828 |
Ejemplares similares
-
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
por: Frank, Samuel, et al.
Publicado: (2022) -
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
por: Claassen, Daniel O., et al.
Publicado: (2017) -
Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?
por: Rodrigues, Filipe B., et al.
Publicado: (2017) -
A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine
por: Patel, Rikinkumar S., et al.
Publicado: (2019) -
The History of Huntington's Chorea
por: Stevens, David L.
Publicado: (1972)